latest news releases from the newsroom
OncoMed Pharmaceuticals Extends License Agreement for Use of MorphoSys's Core Technology
MARTINSRIED, Germany, June 16, 2008 (PRIME NEWSWIRE) -- MorphoSys AG (FSE:MOR) (Prime Standard Segment:TecDAX) announced today that U.S. based biopharmaceutical company OncoMed Pharmaceuticals, Inc. has triggered its pre-existing option to extend the current license agreement between the two companies and has initiated two therapeutic antibody development programs targeting cancer stem cells. Under the extended agreement, which now runs until June 2010, MorphoSys continues to grant OncoMed access to its proprietary antibody library HuCAL GOLD for the use in the research and development of human therapeutic antibodies for the treatment of various cancers by targeting cancer stem cells. The extended agreement includes annual user fees to MorphoSys for OncoMed's access to the HuCAL platform. The two-year extension includes an option for OncoMed to develop and commercialize up to 3 additional HuCAL-derived therapeutic antibodies. In all cases MorphoSys stands to receive exclusive license fees, milestone payments, as well as royalties on end products. Further financial details were not disclosed.
Discover A Portable Egypt -- A Fresh, Intelligent, and Challenging New Novel On One of Today's Most Critical Issues
AMHERST, Mass., June 14, 2008 (PRIME NEWSWIRE) -- In A Portable Egypt, Catherine Madsen explores the world of contemporary abortion politics. Rather than producing thinly disguised propaganda, she explores the platitudes and dogmas of both sides. The characters we meet are real, flesh and blood, caring and complex and often confused. Caught in the ethical and emotional friction between religion and civil rights, they behave in ways that contradict their own opinions. The choices demanded of them by other people and by their own beliefs and desires are often painful, suffocating, ironic, or outright dangerous.